Employing a robust sgRNA transfection-based knockout system into primary mouse T cells from Cas9 transgenic mice, efficient CRISPR-mediated Nr2f6 gene editing for cancer immunotherapeutic purpose has been established. Here, NR2F6 is linked to cancer.